In Memory of Mike Watson
We are so very sad to announce that Mike Watson unexpectedly passed away on Saturday 27 August 2022.
08 September 2022
PRESS RELEASE: VaxEquity Announces Expansion at Cambridge Science Park and of its Senior Team
Appoints Directors of Alliance Management and Finance
13 May 2022
VaxEquity helps move the goalpost for RNA vaccines
The development of messenger RNA (mRNA) vaccines to prevent infection from the SARS-CoV-2 virus has been a public health achievement.
17 January 2022
This was mRNA’s breakout year, and scientists are just getting started
Start-ups are securing money for new applications of mRNA and new versions of the technology
07 December 2021
How to get a job in vaccine development
Our CSO, Dr Robin Shattock was recently interviewed by Nic Fleming at Nature Portfolio on the field of vaccine science, and how researchers can start working in it. When asked on advice to give to early-career researchers to work on vaccines he said, “They must be driven by scientific inquiry. They need to be flexible and resilient.”
15 November 2021
mRNA flu shots move into trials
COVID-19 provided an opportunity to show that mRNA vaccines can work. Now, drug companies are racing to apply the technology platform for influenza.
11 October 2021
AstraZeneca teams up with Imperial offshoot VaxEquity on an RNA 3.0 effort
Last year, Imperial College London professor Robin Shattock was given close to $50 million by the UK government to make an RNA-based Covid-19 vaccine.
23 September 2021
AstraZeneca makes RNA play, teaming up with startup to advance twist on red-hot modality
AstraZeneca is making a play for the red-hot RNA market. Rather than move directly onto turf fought over by the likes of BioNTech, Moderna and Sanofi, AstraZeneca has teamed up with a new British startup that has put a twist on the idea of using nucleic acids to trigger production of a molecule.
23 September 2021
PRESS RELEASE: VaxEquity Announces Strategic Collaboration with AstraZeneca to Commercialise Self-Amplifying RNA Platform
VaxEquity receives upfront equity investment and up to $195 million and royalties in the mid-single digits per programme
23 September 2021
PRESS RELEASE: VXT is the latest member of the UK’s BioIndustry Association
Delighted that VXT is the latest member of the UK’s BioIndustry Association, which has played a such a pivotal role in driving forward COVID-19 diagnostics, tools, therapies and vaccines.
13 July 2020
We are incredibly ambitious and we’re looking for equally ambitious people to join us on this journey to lead the world in realising the full potential of RNA in human health
Get in touch
Thank you for your message
We have recieved your message and will get back to your shortly.